Navigation Links
Solta Medical Reports Second Quarter Results

HAYWARD, Calif., July 26, 2012 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the second quarter ended June 30, 2012. Revenue for the second quarter was $37.3 million, an increase of $8.3 million, or 29%, as compared to the second quarter of 2011. Revenue from Liposonix, the Company's non-invasive fat reduction system, was $9.4 million, which was generated from shipments of 98 systems and associated consumables. Total revenue from treatment tips and consumables for the quarter was $18.2 million, representing 49% of total revenue.  Revenue from the Asia Pacific region grew 32% year-over-year driven primarily from sales of the Company's Thermage® and Clear + Brilliant® brands.

"Liposonix continues to gain traction in the market place and in order to meet demand, we ramped production of Liposonix systems by 40% during the quarter and doubled the production of transducer treatment tips. We expect to increase production over the balance of the year to meet the anticipated demand," said Stephen J. Fanning, Chairman, President & CEO. "Approximately three-quarters of the available Liposonix product was shipped to customers in North America in Q2. We look forward to expanding our Liposonix commercialization efforts in markets outside of North America over the remainder of the year."

GAAP net loss for the quarter was $26.3 million as compared to GAAP net loss of $0.2 million reported for the second quarter of 2011. Non-GAAP net income for the quarter was $2.7 million, or $0.04 per diluted share as compared to non-GAAP net income of $1.4 million, or $0.02 per diluted share for same period last year.

Solta Medical's GAAP results for the second quarter include a $26.0 million charge for a fair value reassessment of the expected earn out payments associated with the acquisition of Liposonix. The total contingent consideration, which includes expected payments over the next seven years, has been increased by $26.0 million to $58.5 million, and is shown on the Company's June 30, 2012 balance sheet as a short-term liability of $22.2 million and a long-term liability of $36.3 million.  The Company's GAAP results for the quarter also include $1.8 million of non-cash amortization and other acquisition related charges, and $1.2 million of non-cash stock based compensation charges. The Company provides non-GAAP financial measures that exclude these charges and expenses. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

"We produced our eleventh consecutive quarter of positive non-GAAP EBITDA and generated $4.0 million in cash flow from operations," said Mr. Fanning. "In addition, non-GAAP operating income of $3.2 million for the second quarter more than doubled from $1.5 million in the prior year, demonstrating our ability to leverage our operating infrastructure."

Also today the Company announced that it has signed a Commitment Letter from Silicon Valley Bank for a new $10 million term loan.  Upon closing and funding, this term loan will provide the Company with additional capital to continue to drive growth and to address future obligations related to the Liposonix acquisition.

"We believe the additional $10 million term loan provides us with sufficient liquidity to support our operations through the next 12 months, including the 2013 contingent payments related to the acquisition of Liposonix.  Nonetheless, we will continue to evaluate opportunities to strengthen our balance sheet," Mr. Fanning concluded.Financial Outlook for 2012The company updated its financial outlook for 2012 as follows:

  • Revenue for the full year 2012 is now expected to be in the range of $142 million to $144 million, representing year-over-year revenue growth of 22% to 24%, driven by sales of the second generation Liposonix system. The Company previously provided a revenue outlook for full year 2012 in the range of $140 million to $143 million.
  • Non-GAAP gross margin is now estimated to be in the range of 64% to 67% for the full year 2012 as compared to the Company's previously issued range of 63% to 66%. Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP gross margin for the six months ended June 30, 2012 was 67.5%.
  • The outlook for positive non-GAAP EBITDA for every quarter and for the full-year 2012 remains unchanged. Non-GAAP EBITDA excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP EBITDA for the six months ended June 30, 2012 was $4.7 million.
  • Non-GAAP PresentationTo supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses.  The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results.  This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets.  There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.

    Conference Call Information The Company will also host a conference call and webcast today, Thursday, July 26, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments.  The dial-in number for the conference call is 877-941-9205 for domestic participants and 480-629-9819 for international participants.

    To access the live webcast of the call, go to Solta Medical's website at and click on Investor Relations. An archived webcast will also be available at

    About Solta Medical, Inc.Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers six aesthetic energy devices to address a range of issues, including skin resurfacing and rejuvenation with Fraxel® and Clear + Brilliant™, body contouring and skin tightening with Liposonix® and Thermage® and acne reduction with Isolaz® and CLARO™. As the innovator and leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Using similar fractional laser technology, Clear + Brilliant is a unique, cost-effective treatment to prevent and improve the early signs of photoaging. For body contouring, Liposonix is a non-surgical treatment to reduce waist circumference with advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat beneath the skin. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. More than two million procedures have been performed with Solta Medical's portfolio of products around the world. For more information about Solta Medical, call 1-877-782-2286 or log on to

    Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding expected continued market acceptance of Liposonix, plans to increase future Liposonix production, the adequacy of our cash resources, and our financial outlook for 2012. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of our systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2011, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated event.

    Web Site:

     Solta Medical, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of dollars, except share and per share data)(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2012201120122011Net revenue 

    $37,262$28,954$69,716$55,405Cost of revenue 

    13,71410,39125,92518,781Gross margin 

    23,54818,56343,79136,624Operating expenses:Sales and marketing 

    13,67311,91527,61923,733Research and development 

    5,0133,64810,3187,213General and administrative 

    4,6153,6089,2757,334Remeasurement of contingent consideration liability

    26,000(484)30,700(484)Total operating expenses 

    49,30118,68777,91237,796Loss from operations 

    (25,753)(124)(34,121)(1,172)Interest income

    219533Interest expense

    (350)(21)(701)(74)Other income and expense, net

    (121)(9)(147)118Loss before income taxes 

    (26,222)(135)(34,964)(1,095)Provision for income taxes 

    6471121136Net loss

    ($26,286)($206)($35,085)($1,231)Net loss per share — basic and diluted

    ($0.43)($0.00)($0.57)($0.02)Weighted average shares outstanding used in calculating net loss per share:Basic and diluted



     Solta Medical, Inc.NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA, NET INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE  (in thousands, except share and per share data)(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2012201120122011GAAP Gross margin

    $23,548$18,563$43,791$36,624GAAP gross margin as % of sales

    63%64%63%66%Non-GAAP adjustments to gross margin:GAAP Gross margin

    $23,548$18,563$43,791$36,624Amortization and other non-cash acquisition related charges

    1,3758443,0331,689Stock-based compensation

    12795239164Non-GAAP gross margin

    $25,050$19,502$47,063$38,477Non-GAAP gross margin as % of sales

    67%67%68%69%GAAP loss from operations

    ($25,753)($124)($34,121)($1,172)Non-GAAP adjustments to net income (loss) from operations:Amortization and other non-cash acquisition related charges

    1,7291,1283,7462,202Remeasurement of contingent consideration liability

    26,000(484)30,700(484)Acquisition-related expenses

    58120151120Severance expenses (credits)

    (11)—19—Stock-based compensation

    1,2098122,3491,481Non-GAAP income from operations

    $3,232$1,452$2,844$2,147Depreciation expenses

    9377631,8751,545Non-GAAP EBITDA

    $4,169$2,215$4,719$3,692GAAP net loss($26,286)($206)($35,085)($1,231)Non-GAAP adjustments to net loss:Amortization and other non-cash acquisition related charges

    1,7291,1283,7462,202Remeasurement of contingent consideration liability

    26,000(484)30,700(484)Acquisition-related expenses

    58120151120Severance expenses (credits)

    (11)—19—Stock-based compensation

    1,2098122,3491,481Non-GAAP net income 

    $2,699$1,370$1,880$2,088GAAP basic net loss per share

    ($0.43)($0.00)($0.57)($0.02)Non-GAAP adjustments to basic loss per share:Amortization and other non-cash acquisition related charges

    $0.03$0.02$0.06$0.04Remeasurement of contingent consideration liability

    $0.42($0.01)$0.50($0.01)Acquisition-related expenses

    $0.00$0.00$0.00$0.00Severance expenses (credits)

    ($0.00)$0.00$0.00$0.00Stock-based compensation

    $0.02$0.01$0.04$0.02Non-GAAP basic net income per share

    $0.04$0.02$0.03$0.03Non-GAAP diluted net income per share

    $0.04$0.02$0.03$0.03GAAP weighted average shares outstanding used in calculating basic net loss per share

    61,719,57560,634,84961,536,05060,269,804GAAP weighted average shares outstanding used in calculating diluted net loss per share

    61,719,57560,634,84961,536,05060,269,804Adjustments for dilutive potential common stock

    5,245,0874,795,2615,053,4394,497,589Weighted average shares outstanding used in calculating non-GAAP diluted net income per share



     Solta Medical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars, except share and per share data)(unaudited)June 30,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents 

    $15,550$17,417Accounts receivable


    16,45216,524Prepaid expenses and other current assets 

    7,8838,626Total current assets 

    54,88055,849Property and equipment, net 

    6,4496,818Purchased intangible assets, net


    96,62096,620Other assets 

    646659Total assets 

    $204,482$209,298LIABILITIES AND STOCKHOLDERS' EQUITYLiabilities:Accounts payable 

    $5,606$5,767Accrued liabilities 

    16,46516,126Current portion of contingent consideration liability

    22,200—Current portion of deferred revenue 

    4,1864,521Short-term borrowings

    7,6237,441Customer deposits 

    880610Total current liabilities 

    56,96034,465Deferred revenue, net of current portion 

    642824Term loan, net of current portion

    13,97316,959Non-current tax liabilities

    2,9992,975Contingent consideration liability

    36,30027,800Other liabilities 

    11092Total liabilities 

    110,98483,115Stockholders' equity:Common stock, $0.001 par value:100,000,000 shares authorized61,921,292, and 61,130,740 shares issued and outstanding at June 30, 2012 and December 31, 2011

    6261Additional paid-in capital 

    200,964198,565Accumulated deficit 

    (107,528)(72,443)Total stockholders' equity

    93,498126,183Total liabilities and stockholders' equity



    SOURCE Solta Medical, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Solta Medical Reports First Quarter Results
    2. Solta Medical to Present at the JMP Securities Healthcare Conference
    3. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
    4. Medical Device Developers - Network at BIOMEDevice Boston Next Week
    5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
    6. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    7. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
    8. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
    9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    10. Essential Medical Dismisses Patent Case against Masimo and Cercacor
    11. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
    Post Your Comments:
    (Date:12/1/2015)...  The migration to value-based care will require ... that help patients stay healthy and reduce healthcare ... enabled, incorporate care guidelines and be reflective of ... also allow all stakeholders to collaborate across care ... That is the vision, however, research by Chilmark ...
    (Date:12/1/2015)... -- --> --> ... (NKI-AVL), among the world,s largest and most prestigious ... Icon™, the company,s latest generation stereotactic radiosurgery system ... --> With the option to use ... Knife Icon offers greatly enhanced flexibility in how ...
    (Date:12/1/2015)... , December 1, 2015 ... segments the concerned market with analysis and forecast of ... orthobiologics report defines and segments the concerned market with ... to the Market Research Report "North American Orthobiologics Market ... Factors & Spinal Stimulation, Stem Cell Therapy, Viscosupplementation), by ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... Middletown, PA (PRWEB) , ... December 01, 2015 ... ... separate environments; however, there are professionals who believe that with innovative technologies and ... services allows the patient to get the benefit of a dual-approach to his ...
    (Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
    (Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
    (Date:12/1/2015)... ... December 01, 2015 , ... SAN ... today announced that the organization has awarded Education and Developmental Therapies (EDT), an ... Award. The award celebrates exceptional special needs providers that excel in synthesizing the ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... the care management and population health arenas, is pleased to announce that VIP ... containment services, has successfully implemented the ACUITY Complete Care™ Management to back their ...
    Breaking Medicine News(10 mins):